Research advances in the roles of EGFR and targeted therapy in triple negative breast cancer
10.3781/j.issn.1000-7431.2023.2306-0301
- VernacularTitle:EGFR在三阴性乳腺癌中的作用及靶向治疗研究进展
- Author:
Jinming CHEN
1
,
2
,
3
;
Qinghua JIANG
;
Zhe CHEN
;
Zhenzhen TIAN
;
Yaguang DENG
;
Yinhong SONG
Author Information
1. 三峡大学肿瘤微环境与免疫治疗湖北省重点实验室,湖北 宜昌 443002
2. 三峡大学感染与炎症损伤研究所,湖北 宜昌 443002
3. 三峡大学基础医学院,湖北 宜昌 443002
- Keywords:
Triple negative breast cancer;
Epidermal growth factor receptor;
Treatment;
Mutation;
Drug resistance
- From:
Tumor
2023;43(10):829-838
- CountryChina
- Language:Chinese
-
Abstract:
In 2022,breast cancer ranks the first in incidence among all malignant tumors worldwide,and it's high recurrence and fatality rate has posed serious threat to human life and health.Triple negative breast cancer(TNBC)is known for its poor prognosis among all types of breast cancer,and is often associated with elevated expression of epidermal growth factor receptor(EGFR).EGFR is widely expressed on the surface of various cells.The signaling pathway mediated by EGFR is mainly involved in cell growth,proliferation and differentiation.EGFR overexpression is often closely related to tumor invasion,metastasis and prognosis.Therefore,elucidating the roles of EGFR in TNBC and developing prevention and treatment strategies correspondingly are helpful to prevent and control the occurrence of breast cancer,and improve patients'quality of life.This review summarizes the research progress in the roles of EGFR,the treatment strategies and drug resistance in TNBC,in order to provide more refence for treating and improving the prognosis of breast cancer.
